Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-399 in Japanese subjects with advanced solid tumors
NCT03311477Phase 1Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2017
- Primary completion
- Mar 2019
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of telisotuzumab vedotin in solid tumor (advanced stage), sponsored by AbbVie Inc. Primary endpoints: Area under the curve from time zero to the last measurable concentration up to 24 months, Maximum Tolerated Dose up to 21 days and 3 more. Started Nov 2017; status: completed.
02
Drugs
telisotuzumab vedotin
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03311477.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311477.